Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Kangtai Biological Products Co., Ltd.
  6. News
  7. Summary
    300601   CNE100002Q33

SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

(300601)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

China's Kangtai Biological, partners agree to run Phase III trial in Chile - Xinhua

05/25/2021 | 03:43am EDT

BEIJING (Reuters) - China's Shenzhen Kangtai Biological Products has reached an agreement with Chilean partners to run a Phase III clinical trial for its COVID-19 vaccine in the Latin American country, state media Xinhua said.

The vaccine, which obtained emergency use approval in China earlier this month, adopts a technology similar to a shot from Chinese vaccine developers Sinovac Biotech already being used in Chile's mass vaccination drive.

In a signing ceremony on Monday, Chile's Advanced Medical Systems And Investment S.A and University of Chile have also agreed with Kangtai on the procurement of the vaccine, Xinhua said, without disclosing details of the purchase.

Xinhua did not specify the regulatory procedures Kangtai and its partners have to go through in order to start the trial in Chile. Kangtai did not immediately respond to request for comment.

Chile has also signed an order to receive doses from China's CanSino Biologics.

The country with a population of around 19 million has confirmed more than 1.3 million cases of the coronavirus since the pandemic began.

Chile has administered at least 17,318,719 doses of COVID-19 vaccines so far.

(Reporting by Roxanne Liu and Ryan Woo; editing by David Evans)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CANSINO BIOLOGICS INC. -3.61% 262 End-of-day quote.48.44%
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. -3.85% 102.4 End-of-day quote.-41.32%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
09/08Shenzhen Kangtai Biological Products Co., Ltd. Announces Recombinant COVID-19..
CI
08/30Shenzhen Kangtai Biological Products Co., Ltd. Proposes Cash Dividend for the..
CI
08/29Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for t..
CI
08/02Shenzhen Kangtai Biological Products Co., Ltd. Announces Philippine Food and ..
CI
07/13SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : Kangtai Biological to Issue $309 Million ..
MT
06/22Phase III Clinical Fieldwork of the Inactivated COVID-19 Vaccine (Vero Cells)..
CI
05/31SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : Kangtai Biological to List 1.3 Million Ne..
MT
05/25China's Kangtai Biological, partners agree to run Phase III trial in Chile - ..
RE
05/21Shenzhen Kangtai Biological Products Co., Ltd. Not to Pay Dividend for the Ye..
CI
05/16SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : China Approves Kangtai Biological's COVID..
MT
More news
Financials
Sales 2021 3 490 M 541 M 541 M
Net income 2021 1 132 M 175 M 175 M
Net cash 2021 3 448 M 534 M 534 M
P/E ratio 2021 61,6x
Yield 2021 0,26%
Capitalization 70 344 M 10 894 M 10 895 M
EV / Sales 2021 19,2x
EV / Sales 2022 12,0x
Nbr of Employees 2 043
Free-Float 96,9%
Chart SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Shenzhen Kangtai Biological Products Co., Ltd. Technical Analysis Chart | 300601 | CNE100002Q33 | MarketScreener
Technical analysis trends SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 102,40 CNY
Average target price 204,43 CNY
Spread / Average Target 99,6%
EPS Revisions
Managers and Directors
Wei Min Du Chairman & General Manager
Xiang Miao Chief Financial Officer & Board Secretary
Zhi Yun Lu Chairman-Supervisory Board
Xiang Ming Li Independent Director
Dong Guang Ma Independent Director
Sector and Competitors